Author

M. Wang

Institutions: Northwestern University, Mayo Clinic, Dana-Farber Cancer Institute

Observed institutions: Northwestern University, Mayo Clinic, Dana-Farber Cancer Institute

OpenAlex ID: A5006485192

A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103

2007 · M. Wang, W. J. Gradishar, et al. · Journal of Clinical Oncology

Works count: 1

Citation count:

H-index:

I10-index: